ACTINIUM PHARMACEUTICALS, INC.
Moat Score — Actinium Pharmaceuticals, Inc.
Total Moat Score
10 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Actinium holds patents covering its antibody-radioisotope conjugate constructs, including Iomab-B, and years of clinical trial data (including the pivotal Phase 3 SIERRA trial) that would be extremely costly and time-consuming for a competitor to replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small, pre-commercial clinical-stage company, Actinium has no manufacturing or operating cost advantage; radioisotope sourcing and specialized manufacturing are cost centers rather than moats at this stage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | If approved, Iomab-B could command specialty/orphan-like pricing given its targeted, underserved patient population, similar to other approved radiotherapies, but this remains theoretical until commercial approval and launch actually occur. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Targeted radiotherapy development and potential commercialization does not involve any network effect between patients or providers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once (and if) established as a standard pre-transplant conditioning option, treating physicians and transplant centers could develop protocol-level reliance, but no switching costs exist today given the pre-commercial stage. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The pool of specialized transplant centers and radiotherapy-capable treatment infrastructure is naturally limited, which could support a favorable competitive structure if Iomab-B reaches commercialization, though this benefit is not yet realized. |